What Is Ozempic® (Semaglutide)?

What Semaglutide Actually Is

Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), a hormone secreted by intestinal L-cells in response to food. The molecule shares roughly 94% amino-acid sequence homology with native GLP-1 but carries a C-18 fatty-acid side chain attached via a linker to lysine at position 26. That modification binds albumin in the bloodstream, extending the drug's half-life to approximately 165 to 184 hours, which is why a single weekly injection maintains therapeutic plasma concentrations throughout the week [1].

Native GLP-1 is degraded within minutes by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide resists DPP-4 cleavage, giving it a clinical half-life far longer than earlier GLP-1 agents such as exenatide (2.4 hours) or liraglutide (13 hours) [2].

Why the Long Half-Life Matters Clinically

A 165-hour half-life means plasma levels stay within a narrow band between injections, which reduces the peaks and troughs seen with shorter-acting agents. Patients using twice-daily exenatide often report greater nausea tied to sharp post-injection peaks. Once-weekly dosing flattens that curve, and in the SUSTAIN-3 trial (N=813) semaglutide 1 mg produced significantly greater HbA1c reduction than exenatide extended-release 2 mg (difference: 0.62 percentage points, P<0.0001) [3].

Molecular Comparisons to Other GLP-1 Agents

| Agent | Dosing Frequency | Half-Life | Route | |---|---|---|---| | Exenatide (Byetta) | Twice daily | ~2.4 hours | Subcutaneous | | Liraglutide (Victoza) | Once daily | ~13 hours | Subcutaneous | | Dulaglutide (Trulicity) | Once weekly | ~5 days | Subcutaneous | | Semaglutide (Ozempic) | Once weekly | ~7 days | Subcutaneous | | Semaglutide (Rybelsus) | Once daily | ~1 week | Oral |

How Ozempic Works in the Body

Semaglutide binds and activates the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor expressed in the pancreas, brain, heart, kidney, and gut. Activation of GLP-1R triggers three coordinated effects that together lower blood glucose after meals [4].

Glucose-Dependent Insulin Stimulation

The drug amplifies insulin secretion from pancreatic beta cells, but only when blood glucose exceeds roughly 70 mg/dL. Below that threshold, insulin secretion does not increase. This glucose-dependency is why semaglutide monotherapy carries a low intrinsic risk of hypoglycemia, unlike sulfonylureas, which stimulate insulin release independent of glucose levels [5].

Glucagon Suppression

Semaglutide suppresses glucagon secretion from alpha cells, reducing hepatic glucose output. Glucagon drives fasting hyperglycemia in type 2 diabetes; blocking its release addresses one of the central defects of the disease [4].

Gastric Emptying and Central Appetite Regulation

The drug slows gastric emptying, which blunts the post-meal glucose spike. GLP-1 receptors in the hypothalamus and brainstem also reduce appetite and increase satiety signals. In the SUSTAIN-1 trial (N=388), patients on semaglutide 1 mg lost a mean of 4.5 kg over 30 weeks versus 0.9 kg on placebo, without a specific diet intervention [6].

FDA-Approved Indications for Ozempic

Type 2 Diabetes Glycemic Control

The FDA approved Ozempic on December 5, 2017, as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes [7]. The approval was supported by the SUSTAIN clinical program, a series of eight phase-3 trials enrolling more than 8,000 patients across diverse comparators.

Across the SUSTAIN 1 to 5 and 7 trials, semaglutide 1 mg reduced HbA1c by a mean of 1.5 to 1.8 percentage points from baseline versus 0.5 to 1.1 percentage points for active comparators including sitagliptin, exenatide ER, insulin glargine, and dulaglutide [3].

Cardiovascular Risk Reduction

In 2020, the FDA expanded the Ozempic label to include reduction of major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) in adults with type 2 diabetes and established cardiovascular disease. This indication rests on the SUSTAIN-6 trial [8].

SUSTAIN-6 (N=3,297, median 2.1 years) showed a 26% relative reduction in MACE with semaglutide versus placebo (6.6% vs. 8.9%, HR 0.74, 95% CI 0.58 to 0.95, P<0.001 for noninferiority, P=0.02 for superiority) [8]. The benefit was driven mainly by a reduction in nonfatal stroke (39% relative risk reduction).

What Ozempic Is NOT Approved For

Ozempic is not FDA-approved as a weight-loss drug. That indication belongs to Wegovy, which contains the same active ingredient at a higher maintenance dose (2.4 mg weekly). Using Ozempic off-label for weight loss in patients without type 2 diabetes is a clinical and insurance coverage question distinct from approved use [7].

Ozempic Dosing and Titration Schedule

The prescribing information specifies a mandatory dose-escalation schedule to reduce gastrointestinal side effects [7]:

| Weeks | Dose | |---|---| | 1 to 4 | 0.25 mg once weekly (initiation dose, not therapeutic) | | 5 to 8 | 0.5 mg once weekly | | 9+ | 1 mg once weekly if additional glycemic control needed | | 9+ | 2 mg once weekly (maximum; approved January 2022) |

The 0.25 mg starting dose has no meaningful glycemic effect. Its sole purpose is tolerability. Advancing to 0.5 mg before week 5 increases the probability of nausea and vomiting without improving glycemic outcomes [7].

Injections may be given any day of the week, at any time of day, with or without food. The injection day may be changed as long as the new injection is at least 48 hours after the previous one [7].

Clinical Trial Evidence: The SUSTAIN Program

SUSTAIN-1: Monotherapy Versus Placebo

SUSTAIN-1 (N=388, 30 weeks) compared semaglutide 0.5 mg and 1 mg to placebo in patients on diet and exercise alone. HbA1c reductions were 1.45 percentage points (0.5 mg) and 1.55 percentage points (1 mg) versus a 0.02-point decrease with placebo (P<0.0001 for both doses) [6].

SUSTAIN-6: Cardiovascular Outcomes

SUSTAIN-6 remains the defining outcomes trial for Ozempic. The 26% reduction in MACE over a median 2.1-year follow-up in a high-cardiovascular-risk population established the drug's role beyond glucose lowering [8]. Rates of new or worsening nephropathy were also lower with semaglutide (3.8% vs. 6.1%, HR 0.64, P<0.001).

SUSTAIN-7: Head-to-Head with Dulaglutide

SUSTAIN-7 (N=1,201, 40 weeks) compared semaglutide 0.5 mg and 1 mg directly to dulaglutide 0.75 mg and 1.5 mg. Semaglutide 1 mg reduced HbA1c by 1.8 percentage points versus 1.4 percentage points for dulaglutide 1.5 mg (P<0.001). Body weight fell by 6.5 kg versus 3.0 kg, respectively (P<0.001) [9].

SELECT Trial: Cardiovascular Benefit Without Diabetes

The SELECT trial (N=17,604), published in 2023, tested semaglutide 2.4 mg (Wegovy dose) in adults with obesity but without diabetes. Semaglutide cut major adverse cardiovascular events by 20% versus placebo (HR 0.80, 95% CI 0.72 to 0.89, P<0.001) over a mean 39.8 months [10]. Although SELECT used the Wegovy formulation, the data reinforce the cardiovascular biology of GLP-1R agonism in general.

Side Effects and Safety Profile

Gastrointestinal Effects

Nausea is the most common adverse effect, reported in 15 to 20% of patients in SUSTAIN trials versus 6 to 8% with placebo [6]. Vomiting and diarrhea each occur in roughly 5 to 10% of users. These effects are dose-dependent and typically peak during the first 4 to 8 weeks of each dose increase before attenuating. Eating smaller, lower-fat meals at injection time reduces severity [7].

Thyroid C-Cell Concerns

The FDA label carries a boxed warning for thyroid C-cell tumors. In rodent studies, semaglutide caused dose-dependent thyroid C-cell adenomas and carcinomas. The relevance to humans is uncertain because humans express fewer GLP-1 receptors in thyroid C-cells than rodents do. The drug remains contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [7].

No cases of MTC causally linked to semaglutide have been confirmed in human clinical trials to date [11].

Pancreatitis

Acute pancreatitis has been reported in patients taking GLP-1 receptor agonists. The absolute incidence in SUSTAIN trials was low (0.3% semaglutide vs. 0.2% placebo) but the causal relationship remains under evaluation by regulatory agencies [7]. Patients with a history of pancreatitis should use Ozempic with caution and discuss risks with their prescriber.

Diabetic Retinopathy

SUSTAIN-6 found a higher rate of diabetic retinopathy complications with semaglutide versus placebo (3.0% vs. 1.8%, HR 1.76, P=0.02) [8]. The proposed mechanism is rapid HbA1c reduction in patients with pre-existing retinopathy, which can transiently worsen retinal blood flow. Patients with pre-existing diabetic retinopathy should have ophthalmologic monitoring when starting therapy.

Hypoglycemia

As monotherapy, semaglutide rarely causes hypoglycemia because its insulin-stimulating effect is glucose-dependent. Risk increases meaningfully when the drug is combined with a sulfonylurea or insulin; the prescribing information recommends reducing the sulfonylurea or insulin dose when adding semaglutide [7].

Ozempic Compared to Wegovy and Rybelsus

All three products contain semaglutide. The differences are dose and indication [12].

| Product | Route | Max Dose | Primary Indication | |---|---|---|---| | Ozempic | Weekly injection | 2 mg | Type 2 diabetes | | Wegovy | Weekly injection | 2.4 mg | Chronic weight management | | Rybelsus | Daily oral tablet | 14 mg | Type 2 diabetes |

Wegovy's approval rested primarily on the STEP-1 trial (N=1,961), where semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [13]. Ozempic at 1 mg typically produces 4 to 6 kg of weight loss as a secondary effect, far less than the Wegovy dose delivers in a weight-loss-focused population.

Oral semaglutide (Rybelsus) has lower bioavailability than the injectable form. The PIONEER-1 trial (N=703) showed Rybelsus 14 mg reduced HbA1c by 1.4 percentage points over 26 weeks, somewhat less than injectable semaglutide 1 mg in comparable trials, due to absorption variability [14].

Who Is a Candidate for Ozempic?

The American Diabetes Association's Standards of Care in Diabetes (2024) recommend a GLP-1 receptor agonist as a preferred second-line agent after metformin in adults with type 2 diabetes who have established atherosclerotic cardiovascular disease, chronic kidney disease, or a need for weight management [15].

Specific contraindications include:

• Personal or family history of MTC or MEN 2
• Known hypersensitivity to semaglutide or any excipient
• Pregnancy (inadequate safety data; insulin remains preferred for gestational glycemic control)

The drug may be used in patients with mild-to-moderate chronic kidney disease; no dose adjustment is required for renal impairment [7].

HealthRX Clinical Decision Framework: Ozempic Candidacy Triage

The HealthRX medical team uses a four-question screen before initiating Ozempic in any patient:

1. Does the patient have a confirmed type 2 diabetes diagnosis (HbA1c above 6.5% on two occasions, or fasting glucose above 126 mg/dL twice)?
2. Is HbA1c above target (typically above 7.0% per ADA, or individualized higher for frail elderly)?
3. Is there a contraindication present (MTC history, MEN 2, prior hypersensitivity to a GLP-1 agent)?
4. Does the patient have established ASCVD, heart failure, or CKD that specifically favors a GLP-1 agent or SGLT-2 inhibitor?

Patients who pass screens 1 and 2 and fail screen 3 are candidates. Screen 4 guides which drug class to prioritize within the broader second-line field.

Practical Administration Guide

Injection Technique

Ozempic is supplied in a pre-filled pen. Inject into the abdomen, thigh, or upper arm subcutaneously. Rotate sites each week to reduce lipohypertrophy. Needles are not reusable; change the needle after every injection [7].

Store unopened pens in the refrigerator at 36 to 46°F (2 to 8°C). After first use, pens may be stored at room temperature (below 86°F / 30°C) or refrigerated for up to 56 days. Do not freeze [7].

Missed Dose Protocol

If a dose is missed, administer it as soon as possible within 5 days of the scheduled date. If more than 5 days have passed, skip the missed dose and resume the regular weekly schedule. Do not double-dose [7].

Drug Interactions

Ozempic slows gastric emptying, which may reduce the rate of absorption of oral co-medications. This effect is particularly relevant for oral contraceptives and levothyroxine, which have narrow therapeutic windows. Patients taking these drugs should discuss timing adjustments with their prescriber [7].

Regulatory and Insurance Field

The FDA approved Ozempic's 2 mg dose in January 2022, expanding options for patients who do not reach target HbA1c on 1 mg [7]. The drug appears on most commercial formularies as a tier 2 or tier 3 specialty drug, with prior authorization commonly required.

List price in 2024 runs approximately $935 per month for a 2 mg pen. Novo Nordisk's Patient Assistance Program (NovoCare) covers patients earning below 400% of the federal poverty level [16]. The Centers for Medicare and Medicaid Services (CMS) negotiated semaglutide as one of the first ten drugs subject to the Inflation Reduction Act price negotiation process for 2026 coverage [17].

Supply shortages affected Ozempic availability throughout 2022 and 2023 as demand from off-label weight-loss prescribing outpaced manufacturing capacity. The FDA removed Ozempic from its drug shortage list in May 2024, though compounded semaglutide remained available from 503B outsourcing facilities during the shortage period [16].

Semaglutide and Kidney Disease

GLP-1 receptor agonists have demonstrated renal protective effects in several trials. In SUSTAIN-6, semaglutide reduced new or worsening nephropathy by 36% (HR 0.64, P<0.001) versus placebo in high-cardiovascular-risk patients with T2D [8].

The FLOW trial (N=3,533), published in 2024, tested semaglutide 1 mg specifically in patients with type 2 diabetes and chronic kidney disease. Semaglutide reduced the primary composite renal outcome (40% decline in eGFR, kidney failure, or renal/cardiovascular death) by 24% versus placebo (HR 0.76, 95% CI 0.66 to 0.88, P<0.001) [18]. This positions Ozempic as a nephroprotective agent alongside SGLT-2 inhibitors in CKD management.